INSR and breast cancer: Even though our findings require validation in an independent cohort of ER+, IGF‐1R‐positive breast cancer patients on adjuvant tamoxifen, our data suggest that IGF‐1R/InsR inhibition might be an overlooked treatment option for patients with tumors harboring an activated IGF‐1R signaling route.